Clinical Trial Update: This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge [Phase 2]

View source ↗

Summary

This update describes a Phase 2 study by GlaxoSmithKline to test whether GSK256066 can protect mild steroid-naive asthmatics from an antigen challenge.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK256066

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED